Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanimilast (CHF6001) add-on to triple therapy in COPD with chronic bronchitis
NCT04636801Phase 3Terminated
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jul 2021
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 30
01
Overview
A Phase 3 trial of tanimilast in chronic obstructive pulmonary disease (COPD), sponsored by Chiesi Farmaceutici S.p.A.. Started Jul 2021; status: terminated.
02
Drugs
tanimilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04636801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04636801.